Tarsus Pharma

$13.41 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Tarsus Pharma

Tarsus Pharmaceuticals Inc. is a late clinical-stage biopharmaceutical company. The Company if focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. Its lead product candidate, TP-03, is a novel therapeutic being developed for the treatment of blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). It is developing TP-03 as an eye drop. It is also focused on developing additional clinical-stage product candidates, including TP-04 and TP-05. TP-04 is being developed for the treatment of rosacea and TP-05 for Lyme prophylaxis and community malaria reduction.

Stock Analysis

last close $13.36
1-mo return -26.8%
3-mo return -16.5%
avg daily vol. 387.1T
52-week high 39.08
52-week low 10.8
market cap. $272M
forward pe -
annual div. -
roe -26.7%
ltg forecast -
dividend yield -
annual rev. $24M
inst own. 76.7%
baraka

Subscribe now for daily local and international financial news

Subscribe